More Quality Problems at Johnson & Johnson (Odious Details Omitted)
Johnson & Johnson (JNJ), which has been dealing with a long series of quality problems in its over-the-counter drug and other operations – recalled 157,000 surgical staplers, used in hemorrhoid treatment, after the Food and Drug Administration issued a severe safety warnings on the products.
We’ll spare you the details, uh, richly reported by the Wall Street Journal.
J&J’s diversification – it’s relatively less reliant on pharmaceuticals than many of its more narrowly-focused competitors, as in Pfizer (PFE), Merck (MRK), Novartis (NVS) and GlaxoSmithKline (GSK) -- is among the factors that has given it a higher valuation, based on PE ratio. But the complexity seems rather hard to manage.
From the editors of YCharts, which includes the just-released YCharts Pro Platinum for professional investors.
Filed under: Company News